<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974883</url>
  </required_header>
  <id_info>
    <org_study_id>08/64/01</org_study_id>
    <secondary_id>ISRCTN46280267</secondary_id>
    <nct_id>NCT00974883</nct_id>
  </id_info>
  <brief_title>Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)</brief_title>
  <acronym>TABUL</acronym>
  <official_title>The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southend University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nuffield Orthopaedic Centre NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center for Rheumatology Berlin-Buch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Giant Cell Arteritis (GCA) causes inflammation and narrowing of blood vessels and can cause
      blindness in one third of patients. It is important that a prompt, accurate diagnosis of GCA
      is made and treatment given as steroids for two or more years. Currently there is no 100%
      accurate test for GCA. Patients usually have new headache and scalp tenderness, typically
      with an abnormal blood test. However, it can be difficult to distinguish non-serious forms of
      headache from GCA; infection produces similar abnormal blood results. If there is a suspicion
      of GCA, treatment with steroids is started straight away. To confirm a diagnosis, the patient
      will need a biopsy of a temporal artery (a minor procedure performed under local anaesthetic
      to remove a sample of one of the scalp arteries). However, up to 44% of patients will have a
      normal biopsy. Therefore it is difficult to know if a patient with a normal biopsy does or
      does not have GCA. Withdrawing steroid treatment may increase the risk of blindness.
      Continuing treatment in a patient without GCA increases the risk of side effects (e.g.,
      weight gain, infection risk, osteoporosis and fracture risk, high blood pressure, diabetes,
      cataracts). It is important to improve diagnostic tests for GCA. Another test to help in
      diagnosing GCA is an ultrasound scan of the arteries in the side of the head and under the
      arms. Ultrasound does not involve surgery; it is a simple test which can be performed as an
      out patient. Gel is applied to both sides of the head and under each arm. A sound probe is
      placed over the artery at each site to produce the scan.

      The investigators' study will examine the role of ultrasound in diagnosis of 402 patients
      with suspected GCA. All patients will have an ultrasound examination in addition to biopsy
      within a week of starting steroids. Patients will be treated according to usual practice.
      After six months, the investigators will reassess the diagnosis. The investigators will look
      at the accuracy of ultrasound compared with or combined with biopsy. The investigators will
      look at how a doctor's knowledge of ultrasound results or biopsy results alone would affect
      the diagnosis and recommendation to continue or stop steroid treatment. The investigators
      will assess whether knowledge of both results together would alter the diagnosis and
      treatment. The investigators will collect information to estimate the costs of different ways
      of diagnosing GCA in relation to the impact on quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OVERALL DESIGN: The overall design consists of a cohort study of 402 participants with
      suspected GCA who will be followed up for 6 months; a cost-effectiveness study comparing
      ultrasound with temporal artery biopsy; a study of observer agreement in evaluating
      ultrasound and temporal artery biopsies; and an expert panel assessing the appropriateness of
      alternative strategies for diagnosing and treating patients with suspected GCA.

      PRIMARY OBJECTIVES:

        1. To evaluate the diagnostic accuracy (sensitivity and specificity) of ultrasound as an
           alternative to temporal artery biopsy for the diagnosis of GCA in patients referred for
           biopsy with suspected GCA.

        2. To evaluate the cost-effectiveness (incremental cost per QALY) of ultrasound instead of
           biopsy in the diagnosis of GCA.

           SECONDARY OBJECTIVES:

        3. To evaluate inter-observer agreement in the assessment of ultrasound and temporal artery
           biopsy.

        4. To elicit expert views on the appropriateness of performing a biopsy following
           ultrasound using clinical vignettes.

        5. To evaluate the diagnostic accuracy (sensitivity and specificity) of the sequential
           diagnostic strategy from 4 as an alternative to temporal artery biopsy alone in the
           diagnosis of GCA.

        6. To evaluate the cost-effectiveness (incremental cost per QALY) of the diagnostic
           strategy from 4 instead of biopsy alone in the diagnosis of GCA.

      DESIGN:

      A prospective cohort study to evaluate the impact of ultrasound or biopsy of temporal
      arteries on diagnosis of GCA and treatment decisions . The cohort study will use a paired
      design, i.e. all participants will have both US and biopsy, with diagnostic performance
      assessed against a composite reference standard diagnosis following final (6 months)
      assessment. To evaluate the impact of US/biopsy results on clinical practice and longer term
      outcomes, we will derive clinical vignettes based on cases recruited to the study, and
      present them to the treating clinician, along with either the ultrasound, or biopsy or both
      results, so that they can indicate diagnosis and proposed treatment. The main
      cost-effectiveness analyses will evaluate incremental cost per quality adjusted life year
      (QALY) on a long term (lifetime) horizon between diagnostic strategies.

      SETTING:

      Outpatient and inpatient rheumatology and ophthalmology departments in 25 National Health
      Service (NHS) trusts in the United Kingdom (UK) (also sites in Europe of required) with
      access to high resolution US.

      TARGET POPULATION: Patients with suspected GCA who would normally require an urgent temporal
      artery biopsy, i.e. referrals from primary care and suspected GCA identified in secondary
      care. Recruitment of participants will be restricted to patients for whom US and biopsy can
      be performed within 7 days of starting high-dose steroids.

      HEALTH TECHNOLOGIES BEING ASSESSED:

      Halo, stenosis, or occlusion assessed by high resolution US; presence of giant cells or
      granulomatous inflammation on temporal artery biopsy.

      MEASUREMENT OF COST AND OUTCOMES:

      Data collection at baseline, 2 weeks and 6 months will include clinical and laboratory
      markers of disease activity, resource use, health-related quality of life (HRQoL) using the
      EuroQol-5D (EQ-5D), and adverse events. Baseline assessment will include retrospective
      assessment of symptoms and erythrocyte sedimentation rate/C-reactive protein (ESR/CRP)
      results before starting steroids. The reference standard diagnosis will be made using a
      composite of American College of Rheumatology classification criteria, GCA-related events,
      and alternative diagnoses using data collected at all assessments. Proposed treatment data
      will be collected from participating clinicians after each test result is released, and
      classified as treatment for GCA (e.g. initiate/continue steroids) or not GCA (e.g.
      withdraw/rapid taper of steroids) to compare changes in proposed treatment and evaluate
      agreement with the reference diagnosis. Unit costs of resources used will be obtained from
      nationally published sources where available. Modelling will estimate the impact of
      diagnostic strategies on clinical outcomes (e.g. GCA complications and steroid related
      adverse events), their costs and impact on HRQoL beyond study follow-up and within study
      follow-up. Probabilities of events, their cost and impact will be obtained from study data, a
      systematic literature review, or in the absence of relevant data, by formal elicitation of
      expert opinion. Costs and benefits will be discounted at 3.5% (National Institute for Health
      and Care Excellence [NICE] guidance) and uncertainty (including modelling assumptions)
      subjected to probabilistic sensitivity analysis and scenario analysis.

      SAMPLE SIZE:

      A sample size of 402 patients provides 90% power at a 5% type I error rate to test the joint
      hypothesis that (i) US has greater sensitivity than biopsy (to detect an increase in
      sensitivity from 76% for biopsy (assuming a 0.24 false negative fraction based on 9-44%
      biopsy-negative GCA) to 87% sensitivity for US; and (ii) to detect specificity of US of no
      less than 0.83 based on an expected specificity of 0.96. This sample size will allow
      estimation of a one-sided rectangular confidence region for US false and true positive
      fractions, assuming 80% prevalence of GCA in patients having a biopsy for suspected GCA, with
      the sample size inflated (gamma=0.1) due to uncertainty in the proportion of cases/controls
      in a cohort design. We will actually recruit 430 cases to allow for possible drop-outs from
      the study. In addition we will recruit 270 individuals for training purposes, to allow each
      centre to learn the technique of temporal artery and axillary artery scanning. Each centre
      will collect 10 such individuals (training cases), who will be of similar age and gender as
      the study cohort, but who will not have temporal arteritis. This is very important in order
      to ensure that observers are trained to recognise the appearances seen in normal (non GCA
      arteries) especially patients with atherosclerosis. Further ultrasound training including a
      video exam (to identify images of both normal and abnormal features of GCA) and a 'hot' case
      assessment (scanning a patient with GCA) will be designed into the ultrasound training
      programme. In addition, we will provide adequate training days (e.g. 2 separate training
      days) when all observers will be trained formally by Dr Schmidt and other ultrasound experts
      to ensure adequate observer agreement. The first training day will be held prior to starting
      the recruitment of patients, and will be repeated after the first year.

      PROJECT TIMETABLE:

      Total: 48 months (UPDATED TO 60 MONTHS SEE BELOW) Month 1-6 Study materials/protocols
      prepared; Ethics and research governance approval complete; Centres trained, approved and
      ready to recruit.

      Month 7-12 Recruitment monitoring report; Quality control report. Month 13-18 Recruitment
      monitoring report; Quality control report; Additional centres (if required) trained, approved
      and ready to recruit; Month 19-24 Recruitment monitoring report; Quality control report.
      Month 25-30 Recruitment monitoring report; Quality control report; Web-based US and biopsy
      assessment developed.

      Month 31-36 Recruitment completed; Clinical vignettes (web-based) developed. Month 37-42
      Follow-up completed; Inter-rater assessment of US and biopsy images analysis competed; Expert
      panel review of vignettes completed.

      Month 43-48 Database cleaned and locked; Analysis completed; statistical analysis and
      economic modelling, report drafting and preparation of papers. Final report completed.

      PLEASE NOTE: 12 MONTH EXTENSION WAS GRANTED BY THE FUNDER (NIHR HTA) IN SEPTEMBER 2012 TO
      EXTEND THE RECRUITMENT PERIOD FROM THE END OF DECEMBER 2012 TO END OF DECEMBER 2013 (A
      FURTHER 12 MONTHS).

      TH END OF STUDY WILL NOW BE DECEMBER 2014

      The study will be overseen by a Trial Steering Committee (TSC) and an independent Data
      Monitoring Committee (DMC)at least 1 meeting per year.

      BIOBANK:

      We will develop a biobank of tissue, serum, DNA and ultrasound video imaging of blood vessels
      in GCA. An important benefit of the primary protocol is that we can use the accumulated
      material for a number of related projects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the diagnostic accuracy of ultrasound vs temporal artery biopsy for diagnosis of suspected GCA and to evaluate the cost-effectiveness (incremental cost per QALY) of ultrasound instead of biopsy in the diagnosis of GCA.</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate inter-observer agreement in the assessment of ultrasound and temporal artery biopsy</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To elicit expert views on the appropriateness of performing a biopsy following ultrasound using clinical vignettes</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the diagnostic accuracy (sensitivity and specificity) of the sequential diagnostic strategy as an alternative to temporal artery biopsy alone in the diagnosis of GCA</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the cost-effectiveness (incremental cost per QALY) of the diagnostic strategy of combined ultrasound and biopsy instead of biopsy alone in the diagnosis of GCA.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific adverse events measured at each assessment; daily and cumulative steroid dose; steroid side effects; and pain or dysaesthesia at the biopsy site.</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of an alternative diagnosis</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of ultrasound in preventing the need for temporal artery biopsies.</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis of performing a screening ultrasound examination plus biopsy as part of the diagnostic workup of all patients with suspected GCA; or of performing a screening ultrasound examination instead of biopsy; or of performing a screening ultrasound</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis of performing a screening ultrasound examination instead of biopsy in cases with a very low probability of GCA as part of the diagnostic workup of all patients with suspected GCA.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of potential harm done to patients by over diagnosis or under diagnosis of GCA as a result of ultrasound use, either alone or in combination with biopsy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of axillary artery ultrasound scanning in contributing to the diagnosis of GCA.</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of proportion of patients with a biopsy positive halo, stenosis, or occlusion assessed by high resolution ultrasound</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of characteristic features of GCA on temporal artery biopsy in relation to clinical and ultrasound findings</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">880</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Suspected GCA</arm_group_label>
    <description>Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound of temporal and axillary arteries</intervention_name>
    <description>Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion</description>
    <arm_group_label>Suspected GCA</arm_group_label>
    <arm_group_label>Training cohort</arm_group_label>
    <other_name>Ultrasound scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Temporal artery biopsy</intervention_name>
    <description>Biopsy of temporal artery from symptomatic side</description>
    <arm_group_label>Suspected GCA</arm_group_label>
    <other_name>Biopsy of temporal artery</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Temporal artery biopsy samples Serum Plasma White cells Video images of temporal and axillary
      arteries
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study cohort: Patients with suspected new giant cell arteritis Training cohort; patients or
        healthy volunteers willing to have temporal artery and axillary artery ultrasound
        examination
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: for the cohort study

          1. A clinical suspicion of new diagnosis of GCA e.g. patients with a new onset of
             headache, scalp tenderness, with or without elevated CRP or ESR, jaw or tongue
             claudication with or without visual loss.

          2. The clinician decides that the patient requires an urgent temporal artery biopsy to
             determine whether or not the diagnosis is GCA.

          3. The patient agrees and provides NHS consent to undergo a temporal artery biopsy as
             part of standard care.

          4. Patients have been started on high dose glucocorticoids or will be started on high
             dose glucocorticoids.

          5. Patients must be willing to attend for an ultrasound scan of their temporal and
             axillary arteries.

          6. Participants must be willing to give informed written consent or willing to give
             permission for a nominated friend or relative to provide written informed assent if
             they are unable to do so because of physical disabilities e.g. sudden onset of
             blindness/vision loss which can be caused by GCA (this will be made clear in the
             ethics approval application).

          7. Must be 18 years of age or over.

        For the training cases

          1. Patients attending hospital outpatient or in patient departments for assessment for
             any condition (apart from giant cell arteritis or polymyalgia rheumatica) or healthy
             staff volunteers.

          2. Above the age of 50 years.

          3. Willing to attend for an ultrasound scan of their temporal and axillary arteries.

          4. Willing and able to give written informed consent.

        Exclusion criteria: for the cohort study

          1. Previous diagnosis of GCA.

          2. Use of high dose glucocorticoid (&gt;20mg prednisolone/day) for management of current
             suspected GCA for more than 7 days prior to the dates of the ultrasound and biopsy.

          3. Long term (&gt;1 month) high dose (&gt;20mg per day at any time) steroids for conditions
             other than PMR, within three months prior to study entry.

          4. Inability to give informed consent (either written consent or verbal assent from a
             relative or carer)

          5. Inability to undergo an ultrasound scans of the temporal and axillary arteries.

          6. Patients with a known cause of headache (not due to GCA), or any condition which would
             preclude the need for a temporal artery biopsy.

          7. Patients who are unable to undergo an ultrasound scan and a temporal artery biopsy
             within 7 days of starting glucocorticoids.

        For the training cases

          1. Diagnosis of suspected GCA or a previous history of diagnosed or suspected GCA.

          2. Inability to give written informed consent.

          3. Inability to undergo an ultrasound scans of the temporal and axillary arteries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raashid A Luqmani, DM FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Hutchings</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike Bradburn</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bhaskar Dasgupta</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southend</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allan Wailoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sheffield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Salmon</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene McNally</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuffield Orthopaedic Centre Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Hamilton</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bristol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colin Pease</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds General Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan McDonald</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konrad Wolfe</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Southend</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Schmidt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Centre for Rheumatology Berlin-Buch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universit√§tsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743 Jena</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Southern Norway</name>
      <address>
        <city>Kristiansand</city>
        <zip>Post box 416, 4605</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuffield Orthopaedic Centre NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stoke Mandeville Hospital</name>
      <address>
        <city>Aylesbury</city>
        <zip>HP21 8AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrave Park Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT0 7JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suffolk NHS Foundation Trust</name>
      <address>
        <city>Bury St. Edmunds</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dudley Group of Hospitals</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gateshead Health NHS Foundation Trust</name>
      <address>
        <city>Gateshead</city>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Great Yarmouth</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Harlow, Essex</city>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds University NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital,</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northampton Hospital</name>
      <address>
        <city>Northampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Hospiital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX1 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Pennine Acute Hospitals NHS Trust</name>
      <address>
        <city>Pennine Rheumatology Centre, Rochdale Infirmary</city>
        <zip>OL12 0NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire</name>
      <address>
        <city>Reading</city>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Hospiital</name>
      <address>
        <city>Romford</city>
        <zip>RM7 0BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital</name>
      <address>
        <city>Southend</city>
        <zip>SSO 0EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ndorms.ox.ac.uk/clinicaltrials.php?trial=tabul</url>
    <description>Website for TABUL study</description>
  </link>
  <link>
    <url>https://weblearn.ox.ac.uk/portal/hierarchy/medsci/department/ndorms/tabul</url>
    <description>Website for TABUL study documents</description>
  </link>
  <reference>
    <citation>Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-8.</citation>
    <PMID>2202311</PMID>
  </reference>
  <reference>
    <citation>Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis. 2006 Aug;65(8):1093-8. Epub 2006 Jan 13.</citation>
    <PMID>16414971</PMID>
  </reference>
  <reference>
    <citation>Borg FA, Salter VL, Dasgupta B. Neuro-ophthalmic complications in giant cell arteritis. Curr Allergy Asthma Rep. 2008 Jul;8(4):323-30. Review.</citation>
    <PMID>18606086</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ultrasound</keyword>
  <keyword>GCA</keyword>
  <keyword>temporal arteritis</keyword>
  <keyword>biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

